Skip to main navigation
Alpine Immune Sciences Alpine Immune Sciences

Main navigation

  • About Us
    • At a Glance
    • Management Team
    • Board of Directors
    • Scientific Advisors
    • Partners
    • Contact Us
  • Pipeline & Programs
    • Pipeline
    • ALPN-101
    • ALPN-202
    • ALPN-303
    • Science & Platform
    • Scientific Publications
  • Clinical Trials
  • Investors
    • Stock Information
    • Analyst Coverage
    • News Release
    • Events & Presentations
    • SEC Filings
    • Governance
    • FAQs
    • Investors Contact
  • Careers
  • No menu assigned!

Committee Composition

Parent ir menu

stock information  |  analyst coverage  |  news releases  |  events  |  sec filings  |  governance  |  faqs  |  investors contact  | 

Investor Relations - Horizontal

news releases  |  events  |  sec filings  |  governance  | 

board of directors  |  leadership  |  documents  |  committee composition  | 

faqs  |  investors contact  | 
Audit Committee Compensation Committee Nominating and Corporate Governance Committee
Robert Conway Audit Committee Nominating and Corporate Governance Committee
Xiangmin Cui Compensation Committee Nominating and Corporate Governance Committee
Natasha Hernday Audit Committee
Christopher Peetz Audit Committee
Peter Thompson, MD Compensation Committee Nominating and Corporate Governance Committee
James N. Topper, MD, PhD Compensation Committee
= Chairperson = Member

Toolkit

  • Contact Us
  • Email Alerts
  • RSS Feeds
  • Print Page
  • Email Page

Contact

188 East Blaine Street
Suite 200
Seattle, WA
98102
206-788-4545

Sitemap

  • About Us
  • Pipelines & Programs
  • Clinical Trials
  • Investors
  • Careers
  • Contact Us
  • Legal

Twitter

@AlpineImmuneSci

LATEST TWEETS

Tweets by @AlpineImmuneSci

© 2021 Alpine Immune Sciences. All Rights Reserved, Alpine Immune Sciences Inc.

Investor Relations - Horizontal

  • News Releases
  • Events
  • SEC Filings
  • Governance
    • Board of Directors
    • Leadership
    • Documents
    • Committee Composition
  • FAQs
  • Investors Contact